Shares of Clorox Co (NYSE:CLX) have been given an average recommendation of “Hold” by the sixteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $134.33.

A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Clorox from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a research report on Monday. Wells Fargo & Co lifted their price target on shares of Clorox from $130.00 to $146.00 and gave the company a “market perform” rating in a research report on Thursday, January 4th. Jefferies Group reaffirmed a “hold” rating and set a $148.00 price target on shares of Clorox in a research report on Thursday, January 4th. Bank of America raised shares of Clorox from an “underperform” rating to a “neutral” rating and set a $155.00 price target on the stock in a research report on Thursday, January 4th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $150.00 price target on shares of Clorox in a research report on Thursday, October 5th.

Shares of Clorox (CLX) traded down $0.18 during mid-day trading on Tuesday, reaching $146.26. 340,800 shares of the company’s stock were exchanged, compared to its average volume of 766,873. The firm has a market capitalization of $18,860.00, a PE ratio of 26.84, a price-to-earnings-growth ratio of 3.84 and a beta of 0.42. The company has a current ratio of 1.10, a quick ratio of 0.77 and a debt-to-equity ratio of 3.02. Clorox has a 1 year low of $118.41 and a 1 year high of $150.40.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.48 billion. Clorox had a net margin of 11.84% and a return on equity of 161.59%. Clorox’s revenue was up 4.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.36 earnings per share. research analysts anticipate that Clorox will post 5.66 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Wednesday, January 24th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.30%. Clorox’s dividend payout ratio is currently 61.65%.

In related news, SVP Matthew T. Laszlo sold 20,051 shares of Clorox stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $130.46, for a total value of $2,615,853.46. Following the completion of the sale, the senior vice president now owns 10,896 shares in the company, valued at $1,421,492.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael R. Costello sold 10,574 shares of Clorox stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the completion of the sale, the senior vice president now owns 34,867 shares of the company’s stock, valued at approximately $4,742,260.67. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Large investors have recently modified their holdings of the stock. Shell Asset Management Co. increased its stake in shares of Clorox by 102.5% in the third quarter. Shell Asset Management Co. now owns 119,382 shares of the company’s stock worth $11,465,000 after buying an additional 60,427 shares during the last quarter. Vident Investment Advisory LLC bought a new stake in shares of Clorox in the third quarter worth $1,477,000. JPMorgan Chase & Co. increased its stake in shares of Clorox by 63.2% in the third quarter. JPMorgan Chase & Co. now owns 417,347 shares of the company’s stock worth $54,269,000 after buying an additional 161,555 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Clorox by 24.6% in the second quarter. Ameriprise Financial Inc. now owns 1,341,272 shares of the company’s stock worth $178,433,000 after buying an additional 265,200 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Clorox by 3.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 44,974 shares of the company’s stock worth $5,992,000 after buying an additional 1,399 shares during the last quarter. Institutional investors and hedge funds own 73.14% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Clorox Co (CLX) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/09/clorox-co-clx-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.